Pharma Pulse: Ipsen’s Global Tazemetostat Withdrawal and FDA Approval of Deucravacitinib for Psoriatic Arthritis

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.

• Ipsen is voluntarily withdrawing tazemetostat (Tazverik) from all markets effectively immediately. This global withdrawal follows safety signals in the confirmatory SYMPHONY-1 trial, which identified concerning patterns of secondary hematologic malignancies. Ipsen is now working closely with the FDA to formally execute the withdrawal and support patient transitions to alternative treatments.
• In other news, the FDA has approved Bristol Myers Squibb's Sotyktu, also known as deucravacitinib, for adults with active psoriatic arthritis. As the first and only TYK2 oral pill for this condition, Sotyktu demonstrated superiority over placebo in Phase 3 trials, significantly improving both joint pain and skin clearance.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.